Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. (Q37535680)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2010

edit

Language	Label	Description	Also known as
English	Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.	scientific article published on April 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

review article

1 reference

stated in

Europe PubMed Central

title

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

main subject

TNF

0 references

TNF inhibitor

0 references

author

Eloisa Bonfa

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

author name string

Nádia Emi Aikawa

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

Jozélio Freire de Carvalho

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

Clovis Artur Almeida Silva

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

publication date

1 April 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

published in

Clinical Reviews in Allergy & Immunology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

volume

38

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

issue

2-3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

page(s)

82-89

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

cites work

Immunogenicity, efficacy and adverse events of adalimumab in RA patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biology of TNF blockade

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological and clinical effects of anti-TNFalpha treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duration of remission of biologic agents for chronic plaque psoriasis.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rheumatoid arthritis and tumor necrosis factor alpha

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19565360

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S12016-009-8140-3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

PubMed publication ID

19565360

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19565360

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19565360%20AND%20SRC:MED&resulttype=core&format=json

retrieved

1 February 2020

ResearchGate publication ID

226141442

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37535680&oldid=2200510209"